Suppr超能文献

丙型肝炎病毒的病毒学与诊断

HCV virology and diagnosis.

作者信息

Roger Steven, Ducancelle Alexandra, Le Guillou-Guillemette Hélène, Gaudy Catherine, Lunel Françoise

机构信息

Laboratoire de Virologie, CHU Angers et Université d'Angers, Laboratoire HIFIH UFR Santé Département Médecine, SFR 4208-UPRES EA3859, BAT IBS - 4 rue Larrey, 49000 Angers, France.

Service de Bactériologie-Virologie-Hygiène, CHRU de Tours, 37000 Tours, France; INSERM U1259, Université de Tours, 37000 Tours, France.

出版信息

Clin Res Hepatol Gastroenterol. 2021 May;45(3):101626. doi: 10.1016/j.clinre.2021.101626. Epub 2021 Feb 23.

Abstract

Hepatitis C virus (HCV) infection is a major cause of severe liver disease including chronic hepatitis, cirrhosis and hepatocellular carcinoma. The HCV burden in public health is estimated at about 71 million people worldwide by World Health Organization (WHO) with at least 400,000 people that died every year from HCV disease [1]. New hepatitis C treatments with oral direct-acting antivirals (DAAs) showing high rates of response, with short treatment duration [2] have been available. HCV can now be eradicated with minimal side effects. Unfortunately, there is no vaccine yet available, but the development of a safe prophylactic vaccine remains a medical priority [3]. For this purpose, Hepatitis B-C subviral envelope particles can be produced by industrialized procedure. It seems to be very promising as this HBV-HCV vaccine candidate has been shown to elicit a broadly cross neutralizing activity against HCV [4]. Despite this revolution in the HCV-treatment, one of major challenge to achieve a global eradication of HCV remains to reduce the under diagnosis. The low rate of diagnosis is a major obstacle in resources limited countries and is mainly due to the cost of molecular tools, that are essential to diagnose and follow chronic HCV infection. In another hand, the mild clinical symptoms observed in HCV chronic disease, may explain that the majority of HCV infected individuals are unaware of their infection, because HCV testing is not generalized, like it is for HIV. HCV was discovered in 1989 after many years of work, by several researchers, who recently obtained the Nobel price [5-7]. This major discovery allowed the description of the HCV genome and later on of the virus replication and cell cycle, and also, importantly, the development of diagnostic tests for the detection of HCV antibodies (Ab) and RNA who were a priority in transfusion. In this review, we will try to get into the virology and cell biology of HCV. Thereafter, we will discuss the different categories of laboratory tests to diagnose/explore HCV infected subjects.

摘要

丙型肝炎病毒(HCV)感染是导致严重肝脏疾病的主要原因,包括慢性肝炎、肝硬化和肝细胞癌。据世界卫生组织(WHO)估计,全球公共卫生领域的HCV负担约为7100万人,每年至少有40万人死于HCV相关疾病[1]。新型口服直接抗病毒药物(DAAs)治疗丙型肝炎的疗效显著,治疗周期短[2]。现在,HCV可以在副作用最小的情况下被根除。不幸的是,目前尚无可用的疫苗,但开发安全的预防性疫苗仍是医学上的优先事项[3]。为此,可以通过工业化程序生产乙型肝炎-丙型肝炎亚病毒包膜颗粒。这种HBV-HCV候选疫苗已被证明能引发针对HCV的广泛交叉中和活性,似乎很有前景[4]。尽管HCV治疗取得了这一革命性进展,但要在全球根除HCV,主要挑战之一仍是减少诊断不足的情况。在资源有限的国家,低诊断率是一个主要障碍,这主要是由于分子检测工具的成本所致,而这些工具对于诊断和监测慢性HCV感染至关重要。另一方面,HCV慢性病中观察到的轻微临床症状,可能解释了大多数HCV感染者未意识到自己感染的原因,因为HCV检测不像HIV检测那样普及。经过多年研究,HCV于1989年被发现,相关研究人员最近获得了诺贝尔奖[5-7]。这一重大发现使得HCV基因组得以描述,随后病毒复制和细胞周期也得以阐明,重要的是,还开发了用于检测HCV抗体(Ab)和RNA的诊断测试,这些检测在输血领域是优先事项。在本综述中,我们将深入探讨HCV的病毒学和细胞生物学。此后,我们将讨论用于诊断/检测HCV感染受试者的不同类别实验室检测。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验